Slow Capital Inc. purchased a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 133,284 shares of the company's stock, valued at approximately $2,379,000. Slow Capital Inc. owned approximately 0.40% of Grail as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Douglas Lane & Associates LLC bought a new stake in shares of Grail in the 4th quarter worth $3,034,000. 180 Wealth Advisors LLC purchased a new stake in shares of Grail during the fourth quarter valued at $1,681,000. Wesbanco Bank Inc. bought a new stake in Grail in the 4th quarter worth about $523,000. Exchange Traded Concepts LLC purchased a new position in Grail in the 4th quarter worth about $507,000. Finally, A. D. Beadell Investment Counsel Inc. bought a new position in Grail during the 4th quarter valued at about $430,000.
Grail Price Performance
Shares of NASDAQ:GRAL traded down $1.23 during trading on Friday, hitting $30.28. The company's stock had a trading volume of 1,747,993 shares, compared to its average volume of 1,077,201. The company has a 50-day moving average of $20.06 and a 200-day moving average of $16.58. Grail, Inc. has a 12 month low of $12.33 and a 12 month high of $32.65.
Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($3.94) earnings per share for the quarter. The business had revenue of $28.65 million for the quarter. Equities research analysts expect that Grail, Inc. will post -65.16 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently commented on GRAL shares. Wolfe Research initiated coverage on shares of Grail in a research note on Friday, November 15th. They issued a "peer perform" rating for the company. Guggenheim assumed coverage on Grail in a report on Thursday, October 17th. They set a "neutral" rating on the stock. Finally, Morgan Stanley began coverage on Grail in a research note on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price target on the stock.
Check Out Our Latest Stock Report on GRAL
Insider Buying and Selling
In related news, CFO Aaron Freidin sold 30,452 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total value of $426,937.04. Following the completion of the sale, the chief financial officer now directly owns 268,277 shares of the company's stock, valued at approximately $3,761,243.54. This represents a 10.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
About Grail
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Recommended Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
